v3.26.3
Fair Value Measurements
 12 Months Ended
Aug. 31, 2026
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
We determine fair value measurements based on the assumptions a market participant would use in pricing an asset or liability. ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a three-level hierarchy that distinguishes between market participant assumptions based on (i) unadjusted quoted prices for identical assets or liabilities in an active market (Level 1), (ii) quoted prices in markets that are not active or inputs that are observable either directly or indirectly for substantially the full term of the asset or liability (Level 2), and (iii) prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement (Level 3).
We utilize valuation methodologies to determine the fair values of our financial assets and liabilities in conformity with the concepts of “exit price” and the fair value hierarchy as prescribed in ASC 820. All valuation methods and assumptions are validated at least quarterly to ensure the accuracy and relevance of the fair values. There were no material changes to the valuation methods or assumptions used to determine fair values during the current period. No transfers between the levels of the fair value hierarchy occurred during the current fiscal period. In the event of a transfer in or out of a level within the fair value hierarchy, the transfers would be recognized on the date of occurrence. We may from time to time be required to remeasure the carrying value of certain assets and liabilities to fair value on a nonrecurring basis. Such adjustments typically arise if we determine that certain of our assets are impaired.
Financial Instruments Recorded at Fair Value
The following table summarizes balances and the fair value hierarchy level of our financial instruments recorded at fair value on a recurring basis as of the dates presented (in millions):
August 31,
20262025
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash and cash equivalents$636.3 $— $— $636.3 $422.5 $— $— $422.5 
Assets in fair value hierarchy636.3 — — 636.3 422.5 — — 422.5 
Other investments(1)
6.0 5.1 
Total assets at fair value$636.3 $— $— $642.3 $422.5 $— $— $427.6 
____________________________________
(1)Includes strategic investments in privately-held entities over which we do not exercise significant influence or control and without readily determinable fair values. Amounts are recorded at cost less any impairment adjusted for observable price changes, if any. These amounts are recorded within Other long-term assets on the Consolidated Balance Sheets.
Nonrecurring Fair Value Measurements
The following table summarizes information related to our nonrecurring fair value measurements in fiscal 2026 as of the dates presented (in millions):
Measurement DateFair Value Hierarchy LevelFair Value
Long-lived intangible assetsAugust 31, 2026Level 3$— 
Right-of-use operating lease assetAugust 31, 2026Level 3— 
Total assets at nonrecurring fair value$— 
Long-Lived Intangible Assets
During the fourth quarter of fiscal 2026, we took actions to accelerate productivity efforts, including the elimination of a brand, which triggered an impairment test for the related intangible assets. Accordingly, we assessed the recoverability of these assets using an undiscounted cash flow model and concluded the carrying values of the assets were not fully recoverable. Based on the significant change in expected use of these assets, we determined their fair values were de minimis at August 31, 2026, and we recorded impairment charges of $2.9 million. These charges are reflected within Special Charges on the Consolidated Statements of Comprehensive Income and relate to our ABL segment.
Right of Use Operating Lease Asset
In fiscal 2026, we discontinued the use of a leased facility. Accordingly, we assessed the recoverability of this asset using an undiscounted cash flow model and concluded that the carrying values of the asset was not fully recoverable, which triggered an impairment test for this asset. Our impairment test indicated that the carrying value exceeded its fair value, which resulted in an impairment charge of $3.1 million. This amount is included within Special charges on the Consolidated Statements of Comprehensive Income and relates to our AIS segment.
Disclosures of Fair Value of Financial Instruments
Disclosures of fair value information about financial instruments, for which it is practicable to estimate that value, are required each reporting period in addition to any financial instruments carried at fair value on a recurring basis as prescribed by ASC Topic 825, Financial Instruments (“ASC 825”). In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows.
Fair value for our senior unsecured public notes is estimated based on discounted future cash flows using rates currently available for debt of similar terms and maturity (Level 2). Our senior unsecured public notes are carried at the outstanding balance, net of unamortized bond discount and deferred costs, as of the end of the reporting period. The estimated fair value of our senior unsecured public notes was $444.1 million and $446.7 million as of August 31, 2026 and 2025, respectively.
We had $200.0 million and $400.0 million of borrowings outstanding under our credit agreements as of August 31, 2026 and August 31, 2025, respectively. Such borrowings are variable-rate instruments that reset on a frequent short-term basis; therefore, we estimate that any outstanding carrying values of these instruments, which are equal to their face amounts, approximate their fair values. See Debt and Lines of Credit footnote of the Notes to Consolidated Financial Statements for further details on our outstanding borrowings.
ASC 825 excludes certain financial instruments and all nonfinancial instruments from its disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value to us. In many cases, the fair value estimates cannot be substantiated by comparison to independent markets, nor can the disclosed value be realized in immediate settlement of the instruments. In evaluating our management of liquidity and other risks, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.